أحد الأهداف الرئيسية لـ Life4me + - منع حالات الإصابة الجديدة بفيروس نقص المناعة البشرية والأمراض المنقولة جنسياً الأخرى والتهاب الكبد الوبائي والسل.

يساعد التطبيق على تأسيس اتصال مجهول بين الأطباء والمصابين بفيروس نقص المناعة البشرية. انها تسمح لك بسهولة تنظيم جدول الدواء الخاص بك وإعداد تذكير خفية وشخصية.

إلى الوراء
١٣ أبريل ٢٠١٧, ١١:٣٩
3989

Math Model Suggests HIV Vaccine Still Has Pivotal Role In Ending AIDS

Math Model Suggests HIV Vaccine Still Has Pivotal Role In Ending AIDS - صورة 1

Scientists from the Yale School of Public Health conducted a major study on the impact and cost-effectiveness of HIV vaccines. According to the results of the work published in the Proceedings of the National Academy of Sciences, even an ineffective (from 50%) vaccine combined with other methods of prevention can prevent 17 million new infections in the coming years.

The researchers, led by Alison Galvani, developed a mathematical model of the HIV epidemic progression, which showed that maintaining the status quo in treatment and diagnosis would lead to 49 million new HIV / AIDS cases in the world in 2015-2035. The use of a vaccine with a relatively low efficiency could reduce this figure down to 32 million.

According to Galvani, even if UNAIDS will achieve its ambitious goals within the 90-90-90 program framework, the additional advantage of a partially effective vaccine would be a huge help in overcoming the pandemic and saving millions of lives around the world.

However, the key problem in implementing such a plan is the fact that vaccines are put into production only with the proven effectiveness of 80-95%, while the creation of an HIV vaccines associated with some difficulties. A live HIV-based vaccine can produce more harm than good, where an inactivated virus vaccine has not shown efficacy above 39% to date.

The last major tests of the HIV vaccine were held in Thailand seven years ago. These days a placebo-controlled trial of such a vaccine is taking place in South Africa. It will be put into production if it will show the efficiency at least 50%. The first results of the study in South Africa will be known in 2020.

مؤلف: ليليا تين

مشاركة على وسائل التواصل الاجتماعي